Pain control through selective chemo-axotomy of centrally projecting TRPV1+ sensory neurons

Abstract

Authorship note: MRS and JKN contributed equally to this work. Conflict of interest:MJI is an inventor on US patent US 8338457 B2, "Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist, " issued to the NIH, and is on the scientific advisory board of Ark Animal Health. JDH has received research support through a cooperative research and development agreement with Sorrento Therapeutics. JKN, ELR, and RMC are employees of Velocity Laboratories, a company that provides fee-for-service behavioral testing using operant pain assays.

Unintended consequences of COVID-19 safety measures on patients with chronic knee pain forced to defer joint replacement surgery

“…Most of the OA patients choose TKA as their last resort, ie, after trying all the available above-mentioned existing drugs and hence very few may reconsider this approach, given that even best of these agents are beneficial only to half of the population taking these medications, not to mention the side effects and potential toxicities in patients with associated comorbidities. 53 (3) Finally, implementing long-term therapeutic interventions focusing on peripheral changes in neural afferent activity arising from the inflamed joint including persistent periarticular delivery of local anesthetics 11 and ablating agents that target the peripheral nerve terminal 25 , 26 , 50 , 54 should be considered. Selective neurotargeting of nociceptive nerve fibers can induce analgesia without compromising motor and sensory modalities unrelated to nociception.…”

“…(3) Finally, implementing long-term therapeutic interventions focusing on peripheral changes in neural afferent activity arising from the inflamed joint including persistent periarticular delivery of local anesthetics 11 and ablating agents that target the peripheral nerve terminal 25 , 26 , 50 , 54 should be considered. Selective neurotargeting of nociceptive nerve fibers can induce analgesia without compromising motor and sensory modalities unrelated to nociception.…”

Ablation of TRPV1+ Afferent Terminals by Capsaicin Mediates Long-Lasting Analgesia for Trigeminal Neuropathic Pain

“…Thus, targeting TRPV11 afferents using topical capsaicin is a promising approach to treating neuropathic pain, especially in patients whose hyperalgesia is likely maintained by sensitized nociceptors (Baron et al, 2017). In addition to topical application, intraarticular or intrathecal injection of capsaicin or resiniferatoxin (RTX), a potent TRPV1 agonist, is also under active development for treating chronic pain (Iadarola et al, 2018;Sapio et al, 2018;Stevens et al, 2019).…”

Investigating the Multitarget Mechanism of Traditional Chinese Medicine Prescription for Cancer-Related Pain by Using Network Pharmacology and Molecular Docking Approach

“…Inhibition of TRPV1 activity was one of the pain treatment methods. In the preclinical study, it has the potential to be a receptor of nonopioid analgesics [ 49 ]. The results of molecular docking showed that the compounds contained in GTF can better combine with TRPV1 and played an analgesic role.…”